Standalone Allergan (AGN) Could Be Worth $300 - RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Standalone Allergan (AGN) Could Be Worth $300 - RBC
April 6, 2016 6:45 AM EDT
DUBLIN, April 6, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced that its merger agreement with Pfizer (NYSE: PFE) has been terminated by mutual agreement, effective today. In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
Allergan reiterated its compelling standalone growth profile and strategy following the... More
April 6, 2016 6:45 AM EDT
NEW YORK--(BUSINESS WIRE)--
Pfizer Inc. (NYSE: PFE) today announced that the merger agreement
between Pfizer and Allergan plc (NYSE: AGN) has been terminated by
mutual agreement of the companies. The decision was driven by the
actions announced by the U.S. Department of Treasury on April 4, 2016,
which the companies concluded qualified as an Adverse Tax Law Change
under the merger agreement.
Pfizer approached this transaction from a position of strength and
viewed the potential combination as an accelerator of existing
strategies, stated Ian Read, Chairman and Chief Executive... More
